InSysBio to present at ACoP9

events
Conference
October 2, 2018

October 2, 2018

InSysBio announces their participation at Ninth American Conference on Pharmacometrics (ACoP9), to be held October 7th to 10th, 2018, at the Loews Coronado Bay Resort near San Diego, CA. The theme of ACoP9 is “Modeling without Bounds”. InSysBio welcomes visitors at the booth #23.

Dr. Tatiana Karelina, Head of the Neurodegenerative Diseases modeling group at InSysBio will make a presentation “Quantitative systems pharmacology model for amyloid pathology investigation” on Monday, October 8 in framework of session 2a “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development”.

InSysBio will present four posters:

Tuesday, October 9, PM session:

  • T-020: “Quantitative Systems Pharmacology (QSP) Model of Bispecific T-Cell Engaging Antibody Constructs for Acute Myeloid Leukemia Treatment” by Oleg Demin Jr (InSysBio), Svetlana Rubina (InSysBio), Theresa Yuraszeck (Amgen), Khamir Mehta (Amgen), Vaishali Chudasama (Amgen), Matthias Klinger (Amgen Research), Cedric Dos Santos (Amgen), Oleg Demin (InSysBio) and Sergey Ermakov (Amgen)

Wednesday, October 10, AM session:

  • W-003: “Semi-Mechanistic Modeling of BRAF and c-MET Inhibitors in the Treatment of Metastatic Melanoma” by Dmitrii Shchelokov and Oleg Demin Jr
  • W-043: “Translational quantitative systems pharmacology model of tau pathology in human and mouse for immunotherapy investigation” by Tatiana Karelina and Alexander Stepanov.

Poster W-043 also was chosen to be presented at the additional poster session to be held during QSP social event on Tuesday, October 9 at 5:30 PM.

Wednesday, October 10, PM session:

  • W-004: “Identification of parameters of QSP models responsible for observed variability in experimental data” by Galina Kolesova and Oleg Demin

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

June 2020
MoTuWeThFrSaSu
1
2
1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
3
4
5
1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
6
7
8
1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
9
10
11
12
1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
13
14
15
16
17
1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
18
19
20
21
22
1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
23
24
25
26
27
28
29
30
1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
     
Upcoming Events
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator